Tag: EMA

July 16, 2021 Off

EMA validates Hutchmed’s Surufatinib

By Dino Mustafić

The European Medicines Agency (EMA) has validated and accepted Chinese HUTCHMED Limited’s marketing authorization application (MAA) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs).